Search

Your search keyword '"Chi, Yayun"' showing total 188 results
Start Over Author "Chi, Yayun"
188 results on '"Chi, Yayun"'

1. R-loop-dependent promoter-proximal termination ensures genome stability

Author

Xu, Congling, Li, Chengyu, Chen, Jiwei, Xiong, Yan, Qiao, Zhibin, Fan, Pengyu, Li, Conghui, Ma, Shuangyu, Liu, Jin, Song, Aixia, Tao, Bolin, Xu, Tao, Xu, Wei, Chi, Yayun, Xue, Jingyan, Wang, Pu, Ye, Dan, Gu, Hongzhou, Zhang, Peng, Wang, Qiong, Xiao, Ruijing, Cheng, Jingdong, Zheng, Hai, Yu, Xiaoli, Zhang, Zhen, Wu, Jiong, Liang, Kaiwei, Liu, Yan-Jun, Lu, Huasong, and Chen, Fei Xavier

Published
2023
Full Text
View/download PDF

2. Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study

Author

He, Min, Hao, Shuang, Ma, LinXiaoxi, Xiu, BingQiu, Yang, BenLong, Wang, ZeHao, Xue, JingYan, Chi, YaYun, Xiong, Min, Chen, JiaJian, Huang, XiaoYan, Liu, XiYu, Wu, SongYang, Xiao, Qin, Huang, Yan, Shui, RuoHong, Cao, AYong, Li, JunJie, Di, GenHong, Yang, WenTao, Hu, Xin, Liu, GuangYu, Yu, KeDa, Jiang, YiZhou, Wang, ZhongHua, Shao, ZhiMing, and Wu, Jiong

Published
2024
Full Text
View/download PDF

8. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer

Author

Chi, Weiru, primary, Xiu, Bingqiu, additional, Xiong, Min, additional, Wang, Xuliren, additional, Li, Pei, additional, Zhang, Qi, additional, Hou, Jianjing, additional, Sang, Yuting, additional, Zhou, Xujie, additional, Chen, Ming, additional, Zheng, Shuyue, additional, Zhang, Liyi, additional, Xue, Jingyan, additional, Chi, Yayun, additional, and Wu, Jiong, additional

Published
2023
Full Text
View/download PDF

13. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer.

Author

Chi, Weiru, Xiu, Bingqiu, Xiong, Min, Wang, Xuliren, Li, Pei, Zhang, Qi, Hou, Jianjing, Sang, Yuting, Zhou, Xujie, Chen, Ming, Zheng, Shuyue, Zhang, Liyi, Xue, Jingyan, Chi, Yayun, and Wu, Jiong

Subjects
HER2 positive breast cancer, EPIDERMAL growth factor receptors, GENETIC transcription regulation, PACLITAXEL, BREAST, CORE needle biopsy, HOMEOBOX genes, TISSUE arrays, PROGNOSIS
Abstract

Although targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer has significantly prolonged survival time and improved patients' quality of life, drug resistance has gradually emerged. This study explored the mechanisms underlying the effect of the motor neuron and pancreatic homeobox 1 (MNX1) genes on drug sensitivity in HER2-positive breast cancer. From July 2017 to 2018, core needle biopsies of HER2-positive breast cancer were collected from patients who received paclitaxel, carboplatin, and trastuzumab neoadjuvant therapy at our center. Based on treatment efficacy, 81 patients were divided into pathological complete response (pCR) and non-pCR groups. High-throughput RNA sequencing results were analyzed along with the GSE181574 dataset. MNX1 was significantly upregulated in the pCR group compared with the non-pCR group in both sequencing datasets, suggesting that MNX1 might be correlated with drug sensitivity in HER2-positive breast cancer. Meanwhile, tissue array results revealed that high MNX1 expression corresponded to a good prognosis. In vitro functional tests showed that upregulation of MNX1 significantly increased the sensitivity of HER2-positive breast cancer cells to lapatinib and pyrotinib. In conclusion, MNX1 may serve as a prognostic marker for patients with HER2-positive breast cancer, and its expression may facilitate clinical screening of patients sensitive to anti-HER2-targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Abstract P3-05-46: scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1- SDC1 axis in tumor metastasis

Author

Zhang, Liyi, primary, Zhang, Qi, additional, Li, Pei, additional, Xiong, Min, additional, Zhou, Yue, additional, Xue, Jingyan, additional, Chen, Ming, additional, Chi, Wei-Ru, additional, Ren, Hengyu, additional, Goh, Chih Wan, additional, Liu, Douwaner, additional, Wangxu, Liren, additional, Chi, Yayun, additional, Xiu, Bingqiu, additional, and Wu, Jiong, additional

Published
2023
Full Text
View/download PDF

19. Abstract P2-16-04: MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer

Author

Chi, Wei-Ru, primary, Xiu, Bingqiu, additional, Xiong, Min, additional, Li, Pei, additional, Zhang, Qi, additional, Li, Lun, additional, Hou, Jianjing, additional, Zhou, Xujie, additional, Sang, Yuting, additional, Chen, Ming, additional, Zhang, Liyi, additional, Xue, Jingyan, additional, Chi, Yayun, additional, and Wu, Jiong, additional

Published
2023
Full Text
View/download PDF

21. Abstract P1-13-15: Elevated TCEAL9 Expression Is Correlated With Trastuzumab-based Neoadjuvant Chemotherapy Resistance In HER2-positive Breast Cancer

Author

Goh, Chih Wan, primary, Chi, Wei-Ru, additional, Zhang, Liyi, additional, Zhang, Qi, additional, Chen, Ming, additional, Xiong, Min, additional, Liu, Douwaner, additional, Ren, Hengyu, additional, Xiu, Bingqiu, additional, Xue, Jingyan, additional, Chi, Yayun, additional, and Wu, Jiong, additional

Published
2023
Full Text
View/download PDF

28. Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization

Author

Zhang, Qi, primary, Xiu, Bingqiu, additional, Zhang, Liyi, additional, Chen, Ming, additional, Chi, Weiru, additional, Li, Lun, additional, Guo, Rong, additional, Xue, Jingyan, additional, Yang, Benlong, additional, Huang, Xiaoyan, additional, Shao, Zhi-Ming, additional, Huang, Shenglin, additional, Chi, Yayun, additional, and Wu, Jiong, additional

Published
2022
Full Text
View/download PDF

31. Development and validation of novel risk prediction models of breast cancer based on stanniocalcin‐1 level.

Author

Huang, Sheng, Chen, Yuyuan, Wu, Jiong, and Chi, Yayun

Subjects
PROGRESSION-free survival, CANCER prognosis, BREAST cancer, DECISION making, PREDICTION models
Abstract

Purpose: The function of stanniocalcin‐1 (STC‐1) in the oncogenesis and progression of tumors has been extensively studied. The purpose of this study was to investigate the relationship between secreted STC‐1 and prognosis in patients with breast cancer (BC) and to determine whether STC‐1 could be a key prognostic factor in BC. Methods: The STC‐1 level was measured by ELISA and clinical data from 1210 female patients with BC were used to develop and validate nomograms. We then verified the models through the plotting of ROC curves and calibration curves, calculating the C‐index, and performing decision curve analyses (DCA). Results: The level of STC‐1 in the peripheral plasma was significantly correlated with the T stage, N stage, clinical stage, grade, hormone receptors, HER‐2 status, and tumor subtype. Cox regression analyses revealed that estrogen receptor(ER) status, N stage, and STC‐1 level were risk factors for overall survival (OS), whereas T stage, N stage, and STC‐1 level were independent prognostic factors for distant disease‐free survival (DDFS) and disease‐free survival (DFS). Both the ROC curve and the C‐index confirmed the high resolution of these models, while the DCA identified the feasibility of their practical application. In addition, the calibration curves indicated good consistency between the predicted and actual survival rates. Conclusion: Nomograms were created based on STC‐1 levels for 3‐, 5‐, and 7‐year OS, DDFS, and DFS of patients with BC respectively. As a key prognostic factor for BC, peripheral blood STC‐1 level can be used clinically as a liquid biopsy indicator. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Coordinated regulation of RNA polymerase II pausing and elongation progression by PAF1

Author

Wang, Zhenning, primary, Song, Aixia, additional, Xu, Hao, additional, Hu, Shibin, additional, Tao, Bolin, additional, Peng, Linna, additional, Wang, Jingwen, additional, Li, Jiabei, additional, Yu, Jiali, additional, Wang, Li, additional, Li, Ze, additional, Chen, Xizi, additional, Wang, Mengyun, additional, Chi, Yayun, additional, Wu, Jiong, additional, Xu, Yanhui, additional, Zheng, Hai, additional, and Chen, Fei Xavier, additional

Published
2022
Full Text
View/download PDF

33. The Prognoses of Young Women With Breast Cancer (≤35 years) With Different Surgical Options: A Propensity Score Matching Retrospective Cohort Study

Author

Li, Pei, Li, Lun, Xiu, Bingqiu, Zhang, Liyi, Yang, Benlong, Chi, Yayun, Xue, Jingyan, and Wu, Jiong

Subjects
Cancer Research, Oncology
Abstract

BackgroundCompared with older patients, young women with breast cancer (YWBCs) have a poorer prognosis and a higher risk of recurrence. Ages ≤35 years are independent risk factors for local recurrence of breast cancer. Surgery is the most important local treatment for YWBC, and there is still a lack of prospective studies comparing surgical options for recurrence and survival. We retrospectively compared the effects of surgical options on disease-free survival (DFS) and overall survival (OS) of YWBC at Fudan University Shanghai Cancer Center (FUSCC).MethodsYWBCs (age ≤35 years) who underwent surgery at FUSCC between 2008 and 2016 were retrospectively analyzed and divided into three groups according to surgical options: 1) breast-conserving surgery (BCS), 2) mastectomy alone (M), and 3) mastectomy with reconstruction (RECON). The DFS and OS outcome rates from the three surgical options were compared using the Kaplan–Meier method and Cox regression model. Propensity score matching (PSM) was also used to balance the baseline characteristics to eliminate selection bias.ResultsA total of 1,520 YWBCs were enrolled with a median follow-up of 5.1 years, including 524 patients (34.5%) who underwent BCS, 676 patients (44.5%) who underwent M, and 320 patients (21.1%) who underwent RECON. The 5-year DFS rates were 96%, 87%, and 93%, respectively (P < 0.001); the 5-year OS rates were 98%, 94%, and 97%, respectively (P = 0.002). Multivariate Cox analysis showed that DFS and OS were significantly improved in patients undergoing BCS compared with those undergoing M, with hazard ratios (HR) of 0.448 (95% CI 0.276–0.728; P = 0.001) and 0.405 (95% CI 0.206–0.797, P = 0.009), respectively. After PSM, DFS and OS rates were significantly improved in patients undergoing BCS compared to patients undergoing M (DFS, P = 0.001; OS, P = 0.009); RECON was also improved compared to patients undergoing M in terms of DFS and OS, but the difference was not statistically significant (DFS, P = 0.164; OS, P = 0.130).ConclusionsThe surgical options were independent factors affecting DFS and OS in YWBC, and the DFS and OS rates were significantly improved in the BCS group compared to those in the M group. BCS is preferred for early YWBC, and RECON is the best option for remodeling the body images of YWBC who do not have breast-conserving conditions.

Published
2022

38. Plasma Extracellular Vesicle Long RNA Profiles in the Diagnosis and Prediction of Treatment Response for Breast Cancer

Author

Su, Yonghui, primary, Zhao, Jingjing, additional, Guo, Rong, additional, Lai, Hongyan, additional, Chi, Weiru, additional, Li, Yuchen, additional, Wang, Jia, additional, Wang, Zhen, additional, Li, Lun, additional, Sang, Yuting, additional, Hou, Jianjing, additional, Xue, Jingyan, additional, Shao, Zhimin, additional, Chi, Yayun, additional, Huang, Shenglin, additional, and Wu, Jiong, additional

Published
2020
Full Text
View/download PDF

46. Abstract P3-01-21: Functional duality of NUAK2 in breast cancer metastases

Author

Wang Jia, Chi Yayun, Wu Jiong, Xiu Bingqiu, Hou Jianjing, Xue Jing-yan, and Li Lun

Subjects
Cancer Research, business.industry, Sentinel lymph node, Cellular homeostasis, Cancer, medicine.disease, Actin cytoskeleton organization, Metastasis, Breast cancer, medicine.anatomical_structure, Oncology, Cancer cell, Cancer research, medicine, business, Lymph node
Abstract

Background: Breast cancer patients with lymph nodes metastasis were proven to have more aggressive biologically phenotypes. This study was aimed to find different biomarker ectopic expression between breast cancer patients' metastatic lymph nodes and primary cancer, and to explore the potential molecular mechanisms. Method: From our previous research, we selected the pairing samples from primary breast cancer with their early stage lymph node metastasis to carry out differential gene expression profiling. Genes with high expression level in sentinel lymph node metastasis were obtained. Then according to the findings of CRISPR/Cas9 screening and the results in relevant literature and online public database, we decided to investigate the role of NUAK2 in our further research. In vitro and in vivo analyses were carried out to determine the potential mechanisms of NUAK2 in lymph node metastases and prognosis. Results NUAK2 belongs to the AMP-activated protein kinase (AMPK) family, with its members controling protein metabolism, polarity, and overall cellular homeostasis actin cytoskeleton organization. The effect of NUAK2 variant expression in breast cancer metastases remains unknown. In this study, it was found that the expression level of NUAK2 was significantly higher in 5 paired metastatic lymph node than that in primary cancer, using Affymetrix GeneChip® Human Transcriptome Array 2.0. From online public database, higher NUAK2 expression level was markedly associated with better metastasis-free survival in breast cancer patients. The effects of NUAK2 on proliferation were investigated by CCK-8 and IncuCyte ZOOM™ assay, respectively. The results demonstrated that knockdown NUAK2 was able to significantly inhibit the proliferation of breast cancer cells. However, for cancer metastases, it was demonstrated that knock-down of NUAK2 significantly accelerated the migration of breast cancer cells, while overexpression of NUAK2 notably inhibited breast cancer cell migration. When promoting proliferation of breast cancer cells, NUAK2 might involve signal pathways of cell cycle. As for the anti-metastasis function, it would regulate cell adhesion, cell motility and microenvironment. Conclusion: Our in vitro study demonstrated that NUAK2 has shown reverse effects of tumor cell proliferation and invasion. The interaction of NUAK2 and cancer cells could be an important role in cell proliferation involved in cell cycle signal pathway, and modulate cell mobility by inducing cell-cell detachment. Its molecular mechanism of dual effect in breast cancer need further investigation. Citation Format: Wang Jia, XUE Jingyan, Hou Jianjing, Xiu Bingqiu, Li Lun, Chi Yayun, Wu Jiong. Functional duality of NUAK2 in breast cancer metastases [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-01-21.

Published
2020

47. Abnormal expression of GADD45B in human colorectal carcinoma

Author

Wang Lisha, Xiao Xiuying, Li Dali, Chi Yayun, Wei Ping, Wang Yiqin, Ni Shujuan, Tan Cong, Zhou Xiaoyan, and Du Xiang

Subjects
Colorectal carcinoma, GADD45B, Carcinogenesis, Relapse, Medicine
Abstract

Abstract Background GADD45B is a member of the growth arrest DNA damage-inducible gene family associated with cell growth control, apoptosis, and DNA damage repair response. The aim of this study is to detect the role of GADD45B in colorectal carcinoma (CRC); the area not studied in depth to date. Methods The mRNA and protein levels of GADD45B were examined by Real-Time quantitative PCR (RT-qPCR) and immunohistochemistry (IHC) in CRC tissues and adjacent noncancerous tissues (ANCT). Over-expression plasmids and SiRNA were used to regulate GADD45B expression in CRC cell lines in vitro and flow cytometry and Western blotting were used to detect apoptotic changes. Results The mRNA and protein levels of GADD45B were significantly higher in CRC tissues than those in ANCT (PP Conclusion GADD45B, a tumor suppressor gene potentially through the p53-mediated apoptotic pathways, is paradoxically overexpressed in CRC and as such may play an unappreciated role in tumorigenesis. The exact mechanism of GADD45B inactivation and overexpression requires further investigation. GADD45B could be a potential therapeutic target for CRC treatment in future.

Published
2012
Full Text
View/download PDF

50. CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription

Author

Huang, Sheng, primary, Chi, Yayun, additional, Qin, Yi, additional, Wang, Ziliang, additional, Xiu, Bingqiu, additional, Su, Yonghui, additional, Guo, Rong, additional, Guo, Liang, additional, Sun, Hefen, additional, Zeng, Chujia, additional, Zhou, Shuling, additional, Hu, Xin, additional, Liu, Sheng, additional, Shao, Zhimin, additional, Wu, Zhaohui, additional, Jin, Wei, additional, and Wu, Jiong, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results